Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteThis is a drug-discovery partnership, not an available cancer treatment. Seattle startup Lila Biologics announced on September 4, 2025, that it had entered a global licensing and multi-target collaboration with Eli Lilly and Company to discover targeted radioligand therapies for solid tumors. Lila plans to use AI-assisted protein design to create tumor-binding molecules; Lilly is expected to lead later preclinical, clinical and commercial work if viable candidates emerge.
What Lila Biologics and Eli Lilly announced
The agreement covers discovery and development of targeted radioligand therapies, also called targeted radiotherapies, for solid tumors. The announcement describes a platform and research collaboration rather than a named medicine. Specific tumor targets, candidate names, radioactive isotopes, financial terms, milestone payments and royalty rates were not disclosed in the available coverage. GeekWire reported the announcement on September 4, 2025, while Inside Precision Medicine described it as a licensing and multi-target collaboration.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
The Biology of Cancer | $207.98 | Buy on Amazon |
| 2 |
|
Introduction to Cancer Biology | $56.88 | Buy on Amazon |
| 3 |
|
Introduction to Computational Cancer Biology | $110.14 | Buy on Amazon |
| 4 |
|
Oxford Textbook of Cancer Biology (Oxford Textbooks in Oncology) | $111.06 | Buy on Amazon |
| 5 |
|
Cancer Chemotherapy, Immunotherapy, and Biotherapy | $238.05 | Buy on Amazon |
What “licensing and collaboration” means
- Licensing: Lilly receives rights connected with one or more Lila programs or the underlying platform.
- Collaboration: Lila and Lilly contribute to research and development rather than one company simply buying an approved drug.
- Future commercialization: Lilly is expected to handle commercialization only if a candidate survives development and obtains regulatory authorization.
Who is Lila Biologics?
Lila Biologics is a Seattle biotechnology company associated with David Baker’s University of Washington Institute for Protein Design. It should not be confused with the university itself or described as a clinical program of the “Baker Lab.” Lila’s founders, CEO Jake Kraft and chief scientific officer Anindya Roy, previously worked as postdoctoral fellows in Baker’s institute. Baker is identified as a Lila co-founder and scientific figure.
The Institute for Protein Design’s technology-transfer listing places Lila among companies linked to Baker’s translational ecosystem. GeekWire reported that Lila had about seven employees when the Lilly collaboration was announced and had raised a $10 million seed round in 2023. The company also describes work on long-acting injectable biologics, primarily for non-oncology uses, alongside its cancer-focused platform.
#1 Best Overall
How the proposed radioligand therapy would work
A radioligand is a targeting molecule connected to a radioactive payload. Lila’s concept uses a small engineered protein, sometimes called a minibinder, rather than relying only on a conventional antibody, peptide or small molecule.
- A computational and laboratory process produces a protein intended to recognize a marker on or near tumor cells.
- Chemistry links that protein to a radioactive isotope or another radiation-delivery payload.
- The resulting molecule circulates and binds preferentially to tissue carrying the selected marker.
- Radiation damages nearby cancer cells.
- The design aims to keep exposure in tumors while clearing relatively quickly from healthy tissue.
Lila describes its platform as combining an AI-powered protein-design engine with high-throughput discovery. The Baker Lab explains that this type of work alternates computational design with experiments to test whether proteins fold, bind and perform as intended. AI proposes or optimizes molecular designs; it does not replace laboratory validation, animal studies, toxicology or clinical trials.
Rank #2
Why use small designed proteins?
Smaller binders could, in principle, move through the tumor microenvironment more effectively and leave healthy tissue faster than large antibody-based constructs. The Washington Research Foundation has described this rationale for minibinder radiotherapy: conventional radiolabeled antibodies may circulate for long periods, whereas smaller engineered binders might combine tumor penetration with faster clearance. Those are design objectives and development hypotheses, not proven benefits for patients.
| Potential advantage | Unresolved trade-off |
|---|---|
| Small size may improve penetration into solid tumors. | Rapid elimination could occur before enough material accumulates in a tumor. |
| Faster clearance might reduce radiation exposure to healthy tissue. | Radiation can still affect healthy tissue, especially when a target is also present outside the tumor. |
| Computer-aided design may tune affinity, stability and circulation time. | Designed proteins still must demonstrate stability, solubility, manufacturability and acceptable immunogenicity. |
| High-selectivity binding is intended to limit nonspecific uptake. | Solid tumors are heterogeneous, so some cancer cells may not express the selected marker. |
Linker chemistry and isotope attachment can also change a protein’s behavior. Success in an animal model would not establish safety or efficacy in people.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Rank #3
What Lilly is expected to do
Company statements reported by GeekWire indicate that Lilly is expected to conduct IND-enabling studies, clinical development and commercialization. IND-enabling work generally includes preclinical pharmacology, toxicology and manufacturing information needed to support an application to begin human testing. An investigational new drug (IND) filing or authorization to start a trial would still not mean the product is approved for sale.
Lila’s role is to apply its protein-design platform and advance candidate molecules. The partnership does not establish that Lilly has selected a final drug candidate, nor that any program will reach a trial.
How far along is the program?
The available reporting places the collaboration at an early discovery or preclinical stage. Lila said it hoped to deliver a candidate protein to Lilly within three to six months of the September 2025 announcement. Trade coverage also reported a company ambition to reach the clinic in 2027. That was a projection, not a confirmed milestone.
| Development stage | Status supported by the available information |
|---|---|
| Target and protein discovery | Subject of the Lila-Lilly collaboration. |
| Candidate handoff | Lila hoped to provide a candidate within three to six months of the announcement; completion is not independently established here. |
| IND-enabling studies | Expected Lilly responsibility if a suitable candidate is selected; no public results are identified. |
| Human clinical trials | No verified trial entry is established in the reviewed sources by August 18, 2026. |
| Regulatory approval or patient access | No approval or availability is established. |
What remains unknown
- The cancer types and tumor antigens being targeted.
- The identity of any lead molecule or development code.
- The radioactive isotope, linker and dosing approach.
- The number of Lilly targets covered by the agreement.
- Clinical-trial identifiers, human safety data and efficacy results.
- Upfront payments, milestones, royalties and other economic terms.
Because the targets are undisclosed, outsiders cannot yet judge how widely a future therapy might apply or how it would compare with existing radioligand approaches.
Recommended Free Tools
Best Value
Can patients receive this therapy now?
No evidence in the available sources indicates that a Lila-Lilly therapy is available to patients. A candidate would need to complete laboratory and animal testing, obtain authorization to begin clinical trials, demonstrate safety and benefit in people, and receive marketing approval. Even a successful program would likely be limited to patients whose tumors carry the relevant target and who meet a future trial or label’s eligibility requirements.
How this fits the broader Baker Lab startup ecosystem
The Institute for Protein Design has helped translate protein-design research through companies including Lila, Vilya, Monod Bio, Xaira Therapeutics, Icosavax and Sana Biotechnology, among others. The institute’s technology-transfer page also notes that Prospect Genomics was acquired by Eli Lilly and Structural GenomiX in 2001. That history demonstrates commercial activity around Baker’s research, but it does not validate Lila’s particular radiotherapy platform or predict its clinical outcome.
What could make the program succeed or fail
- A selected binder must reach tumors at useful levels while avoiding unacceptable healthy-tissue radiation.
- The target must be present consistently enough across a cancer, despite tumor heterogeneity.
- The protein must remain stable, manufacturable and chemically compatible with its radioactive payload.
- Pharmacokinetics, toxicology and immunogenicity must support repeated dosing.
- The clinical benefit must be meaningful compared with existing treatments and radioligand medicines.
- The collaboration could end, a candidate could fail testing, or Lilly could redirect resources before a trial.
The Bottom Line
Lila Biologics’ agreement with Eli Lilly is notable validation of an AI-assisted, small-protein approach to targeted radiotherapy research. It remains an investigational discovery partnership: no specific candidate, human trial, approval or patient access has been established.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
